DeepMed Research

Pasireotide

Generic Name: Pasireotide

Brand Names: Signifor

Drug Type: Small Molecule

Chemical Formula: C_₅₈H_₆₆N_₁₀O_₉

CAS Number: 396091-73-9

Unique Ingredient Identifier: 98H1T17066

Background: Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.

Indication: For the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery has not been curative or is not an option.

Associated Conditions: Acromegaly, Cushing's Disease

Clinical Trials

Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor

Phase 2

Recruiting

Conditions: Desmoplastic Small Round Cell Tumor
Synovial Sarcoma

Interventions: Drug: Signifor

First Posted Date: 2024-06-13

Last Posted Date: 2025-01-13

Lead Sponsor: University Hospital Heidelberg

Target Recruit Count: 28

Registration Number: NCT06456359

Locations: 🇩🇪
Klinikum Stuttgart- Olga Hospital Zentrum für Kinder-, Jugend und Frauenmedizin, Stuttgart, Baden-Württemberg, Germany
🇩🇪
Klinikum Stuttgart Studienzentrale Stuttgart Cancer Center, Tumorzentrum Eva-Mayr-Stihl, Stuttgart, Baden-Württemberg, Germany
🇩🇪
Universitätsklinikum Essen Pädiatrische Hämatologie und Onkologie, Essen, Nordrhein-Westfalen, Germany

and more 1 locations

A Study of Pasireotide in People With Prolactinoma

Phase 2

Recruiting

Conditions: Prolactin-Producing Pituitary Tumor

Interventions: Drug: Pasireotide
Other: SF-36 and HADS

First Posted Date: 2024-03-06

Last Posted Date: 2024-12-30

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 10

Registration Number: NCT06295952

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States

and more 4 locations

Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia

Phase 2

Recruiting

Conditions: Post-Bariatric Hypoglycemia

Interventions: Drug: Pasireotide Diaspartate

First Posted Date: 2023-07-03

Last Posted Date: 2025-05-09

Lead Sponsor: RECORDATI GROUP

Target Recruit Count: 72

Registration Number: NCT05928390

Locations: 🇺🇸
Stanford University School of Medicine, Endocrinology, 800 Welch Road,, Palo Alto, California, United States
🇺🇸
Georgia Clinical Research, LLC, 2878 Five Forks Trickum SW, Suite 2A, Lawrenceville, Georgia, United States
🇺🇸
Northwestern University - Feinberg School of Medicine - Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

and more 28 locations

Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis

Phase 2

Terminated

Conditions: Peritoneal Carcinomatosis

Interventions: Other: Saline water
Drug: Pasireotide 0.9 MG/ML

First Posted Date: 2021-04-01

Last Posted Date: 2024-02-08

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 6

Registration Number: NCT04826432

Locations: 🇫🇷
Gustave Roussy, Villejuif, France

Impact of Pasireotide on Postoperative Pancreatic Fistulas Following Distal Resections

Completed

Conditions: Surgical Complications

Interventions: Drug: Pasireotide 0.9 MG/ML

First Posted Date: 2020-02-24

Last Posted Date: 2020-02-24

Lead Sponsor: Helsinki University Central Hospital

Target Recruit Count: 258

Registration Number: NCT04281680

A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: HTL0030310
Drug: Pasireotide
Drug: Placebo

First Posted Date: 2019-02-20

Last Posted Date: 2025-02-19

Lead Sponsor: Nxera Pharma UK Limited

Target Recruit Count: 42

Registration Number: NCT03847207

Locations: 🇬🇧
Quotient Sciences, Nottingham, United Kingdom

Pasireotide in the Treatment of Hypoglycemia Following Gastric Bypass Surgery

Phase 4

Conditions: Hypoglycemia, Reactive

Interventions: Drug: Pasireotide 0.3 MG/ML
Diagnostic Test: Meal tolerance test (MTT)

First Posted Date: 2018-05-02

Last Posted Date: 2018-07-05

Lead Sponsor: Zealand University Hospital

Target Recruit Count: 5

Registration Number: NCT03514576

Locations: 🇩🇰
Zealand University Hospital, Køge, Denmark

Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia

Phase 1

Completed

Conditions: Post Gastrointestinal Tract Surgery Hypoglycaemia
Hyperinsulinemic Hypoglycemia

Interventions: Drug: Pasireotide

First Posted Date: 2017-04-06

Last Posted Date: 2021-09-29

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 1

Registration Number: NCT03103009

Locations: 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States

Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment

Phase 4

Completed

Conditions: Cushing Disease

Interventions: Drug: Pasireotide 0.6 MG/ML

First Posted Date: 2017-03-15

Last Posted Date: 2017-10-27

Lead Sponsor: University of Palermo

Target Recruit Count: 24

Registration Number: NCT03080181

Pasireotide in Hyperinsulinemic Hypoglycemia

Phase 2

Withdrawn

Conditions: Congenital Hyperinsulinism
Hyperinsulinism
Insulinoma

Interventions: Drug: Saline Solution
Drug: Pasireotide 0.6Mg Solution for Injection

First Posted Date: 2017-02-15

Last Posted Date: 2021-05-14

Lead Sponsor: Montefiore Medical Center

Registration Number: NCT03053284

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy